Drug Trial Radar · NCT02794285
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
559
Actual
Start
Jun 30, 2016
Primary completion
Dec 21, 2021
Study completion Dec 21, 2021
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- PRA Health Sciences
- First posted
- Jun 9, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.
Conditions
- Active Systemic Lupus Erythematosus
Interventions
AnifrolumabBiological
Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
PlaceboDrug
Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs)Time frame: Up to a maximum of 1114 days
- EAIRs of Serious Adverse Events (SAEs)Time frame: Up to a maximum of 1114 days
Locations
175 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
El Cajon, California
Research Site
Hemet, California
Research Site
La Jolla, California
Research Site
Los Alamitos, California
Research Site
Los Angeles, California
Research Site
San Leandro, California
Research Site
Thousand Oaks, California
Research Site
Upland, California
Research Site
Aurora, Colorado
Research Site
Denver, Colorado
Research Site
Bridgeport, Connecticut
Research Site
Brandon, Florida
Research Site
DeBary, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Ormond Beach, Florida
Research Site
Tampa, Florida
Research Site
Vero Beach, Florida
Research Site
Atlanta, Georgia
Research Site
Decatur, Georgia
Research Site
Lawrenceville, Georgia
Research Site
Marietta, Georgia
Research Site
Boise, Idaho
Research Site
Idaho Falls, Idaho
Research Site
Cumberland, Maryland
Research Site
Hagerstown, Maryland
Research Site
Grand Rapids, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Nashua, New Hampshire
Research Site
Freehold, New Jersey
Research Site
Las Cruces, New Mexico
Research Site
Brooklyn, New York
Research Site
Great Neck, New York
Research Site
New Hyde Park, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Charlotte, North Carolina
Research Site
Charlotte, North Carolina
Showing 40 of 175 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.